Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma.

(2017) J. F. San-Miguel et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

(2010) Ruben Niesvizky et al.   CANCER

The Oral Histone Deacetylase Inhibitor LBH589 Is a Potential and Promising Therapeutic Agent in Multiple Myeloma after at Least Two Lines of Chemotherapy Including Bortezomib or Lenalidomide

(2010) Stefan Schmitt et al.   ONKOLOGIE

Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

(2009) Peter Atadja   CANCER LETTERS

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

(2009) E. M. Ocio et al.   HAEMATOLOGICA

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

(2008) L. Ellis et al.   CLINICAL CANCER RESEARCH

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

(2008) Paul Richardson et al.   LEUKEMIA & LYMPHOMA